Six weeks of steroids beat three for mild immune-related pneumonitis

Design

Randomised non-inferiority trial

Population

106 patients with grade 1–2 immune checkpoint inhibitor pneumonitis, median age 72, in Japan

Primary outcome

Treatment success at 8 weeks

Effect

66.7% (3 weeks) vs 85.2% (6 weeks); difference −18.5 points; non-inferiority not shown

Steroid duration for pneumonitis caused by immune checkpoint inhibitors has rested on expert opinion. This Japanese trial, the first randomised test of the question, assigned 106 patients with grade 1–2 pneumonitis (median age 72; 73% grade 2) to a 3-week or the guideline-recommended 6-week corticosteroid taper.

Treatment success at 8 weeks — room-air saturation of at least 90% without steroid escalation or extension — was 66.7% with 3 weeks and 85.2% with 6 weeks (difference −18.5 points). Non-inferiority of the shorter course was not shown, and a prespecified exploratory analysis favoured 6 weeks. Grade 3 or worse adverse events were more frequent with 6 weeks (24% vs 12%), all manageable. Quality of life and overall survival did not differ.

For clinicians tempted to shorten steroids to limit toxicity or to restart immunotherapy sooner, this trial supports keeping to six weeks for mild pneumonitis. The trial was small and conducted in Japan, and the higher adverse event rate with longer steroids deserves attention, but the gap in treatment success was large.

• Continue a six-week corticosteroid taper for grade 1–2 checkpoint-inhibitor pneumonitis, as guidelines advise.
• Do not shorten the taper to three weeks to speed a return to immunotherapy.
• Monitor for steroid adverse effects, which were more frequent with six weeks.
• Reassess oxygen saturation and symptoms at the end of the taper and again at eight weeks.

Why it matters

It replaces opinion with trial evidence on a decision oncology and respiratory teams make often.

Don't overread it

The superiority finding for six weeks comes from an exploratory analysis in 106 patients.

The statistics, in plain English

Non-inferiority required the shorter course to be no more than a set margin worse. The difference was −18.5 points with an 80% interval of −29.0 to −7.9, so three weeks was clearly worse, not merely uncertain. Survival was similar (HR 1.03, 0.46–2.29), though the trial was not powered for it.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.